Cancer Family
Malignant Neoplasm
CI-CAN-00000025CAExplore in graph →
20,108 active trials259 approved drugs3,741 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000025CAExplore in graph →
Clinical trials
90,662 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11,158)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00958737 | Combination Chemotherapy for 3 Months or 6 Months in Treating Patients With Stage III Colon Cancer(IDEA) | unknown | Phase 3 | 2,000 | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 1 | Sep 29, 2023 | clinicaltrials |
| NCT02338518 | Comparison of SEEOX and SOX Regimens in Stage ⅢB/ⅢC Gastric Cancer Patients(SVOSA) | unknown | Phase 3 | 297 | Jinling Hospital, ChinaOTHER | 1 |
| Sep 29, 2023 |
| clinicaltrials |
| NCT01949337 | Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer | unknown | Phase 3 | 1,311 | Alliance for Clinical Trials in OncologyOTHER | 3 | Sep 28, 2023 | clinicaltrials |
| NCT02614534 | Clinical Trial to Evaluate Safety and Efficacy of Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) With Mitomycin C Used During Surgery for Treatment of Locally Advanced Colorectal Carcinoma(HIPECT4) | unknown | Phase 3 | 200 | Maimónides Biomedical Research Institute of CórdobaOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT06049901 | Nitazoxanide in Patients With Metastatic Colorectal Cancer | unknown | Phase 3 | 60 | Tanta UniversityOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT05986331 | Clinical Study of the Efficacy and Safety of BCD-201 and Keytruda in Subjects With Advanced Melanoma | unknown | Phase 3 | 366 | BiocadINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT06031597 | Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy | unknown | Phase 3 | 105 | Zhejiang Cancer HospitalOTHER | 0 | Sep 13, 2023 | clinicaltrials |
| NCT04311073 | Prophylactic Tranexamic Acid During Minimally Invasive Myomectomies | unknown | Phase 3 | 50 | Eastern Virginia Medical SchoolOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT03759093 | CURATE.AI Optimized Modulation for Multiple Myeloma | unknown | Phase 2 / Phase 3 | 20 | National University Hospital, SingaporeOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT05755048 | FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer | unknown | Phase 3 | 314 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 1 | Sep 1, 2023 | clinicaltrials |
| NCT06020352 | The Efficacy and Safety of KN046 Combined With Axitinib | unknown | Phase 2 / Phase 3 | 20 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Aug 31, 2023 | clinicaltrials |
| NCT04741438 | Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype(RAR-Immune) | unknown | Phase 3 | 96 | Centre Leon BerardOTHER | 1 | Aug 30, 2023 | clinicaltrials |
| NCT05994339 | Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung Cancer | unknown | Phase 2 / Phase 3 | 40 | Laibin People's HospitalOTHER | 0 | Aug 29, 2023 | clinicaltrials |
| NCT06016400 | Using Vitamin D to Reduce Oral Mucosal Inflammation in Chemotherapy Patients With Oral Squamous Cell Carcinoma | unknown | Phase 2 / Phase 3 | 412 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT02031939 | Randomized Controlled Study on Optimize Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer | unknown | Phase 3 | 556 | Sun Yat-sen UniversityOTHER | 1 | Aug 25, 2023 | clinicaltrials |
| NCT05985187 | Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer. | unknown | Phase 3 | 412 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Aug 14, 2023 | clinicaltrials |
| NCT03952403 | A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | unknown | Phase 3 | 643 | Shanghai Henlius BiotechINDUSTRY | 1 | Aug 8, 2023 | clinicaltrials |
| NCT03790553 | Comparing 61.2 Gy Radiotherapy Dose Versus 50.4 Gy Radiotherapy Dose for Locally Advanced Esophageal Carcinoma | unknown | Phase 3 | 646 | Fudan UniversityOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT04262635 | Cetuximab Plus Capecitabine as Maintenance Treatment in RAS and BRAF wt Metastatic Colorectal Cancer(C-CLASSIC) | unknown | Phase 3 | 80 | Sun Yat-sen UniversityOTHER | 1 | Aug 2, 2023 | clinicaltrials |
| NCT03950154 | Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Recurrent and Metastatic Colorectal Cancer | unknown | Phase 3 | 198 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT04532229 | Nimotuzumab in Combined With Chemoradiotherapy to Treat the Newly Diagnosed Diffuse Intrinsic Pontine Glioma in Children | unknown | Phase 3 | 48 | Biotech Pharmaceutical Co., Ltd.OTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT05313958 | Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children(SCCLG-M5) | unknown | Phase 2 / Phase 3 | 43 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT05433480 | A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer | unknown | Phase 3 | 274 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 27, 2023 | clinicaltrials |
| NCT05020392 | Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma | unknown | Phase 3 | 24 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 25, 2023 | clinicaltrials |
| NCT05948072 | Cetuximab+mFOLFOX6 VS. mFOLFOX6 Alone in RAS/BRAF Wild Type Patients With High-Risk Resectable CRLM | unknown | Phase 3 | 250 | Fudan UniversityOTHER | 1 | Jul 17, 2023 | clinicaltrials |
| NCT01579734 | Phase III, Randomized, Double Blind Trial Low Dose Tamoxifen Versus Placebo in Hormone Replacement Therapy (HRT) Users(HOT) | unknown | Phase 3 | 1,884 | European Institute of OncologyOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT01968200 | Prevention of Anthracycline-induced Cardiotoxicity(ICOS-ONE) | unknown | Phase 3 | 268 | European Institute of OncologyOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT04797884 | Electromagnetic Fields Versus Placebo For Child-Pugh A and B Patients With Advanced Hepatocellular Carcinoma(ARTEMIS) | unknown | Phase 2 / Phase 3 | 166 | THERABIONIC INC.OTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT04201561 | High Dose Inorganic Selenium for Preventing Chemotherapy Induced Peripheral Neuropathy(SELENIUM) | unknown | Phase 3 | 68 | Seoul National University HospitalOTHER | 1 | Jun 26, 2023 | clinicaltrials |
| NCT05263219 | DEB-TACE+HAIC vs. HAIC for Large HCC | unknown | Phase 3 | 230 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT02948543 | Adding Mitomycin to BCG as Adjuvant Intravesical Therapy for High-risk Non-Muscle-invasive Bladder Cancer(BCG+MM) | unknown | Phase 3 | 501 | University of SydneyOTHER | 2 | Jun 18, 2023 | clinicaltrials |
| NCT04578613 | ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL | unknown | Phase 3 | 218 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Jun 5, 2023 | clinicaltrials |
| NCT05264883 | Venetoclax+HMA+Aclarubicin Versus Venetoclax+HMA in Treatment-Naive Elderly Patients With AML | unknown | Phase 3 | 170 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | May 30, 2023 | clinicaltrials |
| NCT04233151 | QL1203 In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy and Safety | unknown | Phase 3 | 590 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 26, 2023 | clinicaltrials |
| NCT03700905 | Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant Therapy(IMSTAR-HN) | unknown | Phase 3 | 276 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT05179733 | The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years | unknown | Phase 3 | 280 | Ruijin HospitalOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT03321539 | Phase Ⅲ Trial of Adjuvant Chemotherapy in Patients With N2-3 Nasopharyngeal Carcinoma | unknown | Phase 3 | 216 | Sun Yat-sen UniversityOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT05866172 | HAIC Combined Withzoledronic Acid for the Prevention of Bone Metastases in Advanced HCC | unknown | Phase 3 | 264 | Sun Yat-sen UniversityOTHER | 1 | May 19, 2023 | clinicaltrials |
| NCT05157776 | A Phase III Trial of Neoadjuvant Sintilimab and Chemotherapy for NSCLC Harboring No Driver Mutations | unknown | Phase 3 | 72 | Tongji UniversityOTHER | 1 | May 9, 2023 | clinicaltrials |
| NCT02974556 | Proactive Management of Endoperitoneal Spread in Colonic Cancer(PROMENADE) | unknown | Phase 3 | 140 | University of Roma La SapienzaOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT05841992 | Al18F-PSMA-617 and 68Ga-PSMA-617 PET/CT Imaging in the Same Group of Prostate Cancer Patients | unknown | Phase 2 / Phase 3 | 100 | Peking Union Medical College HospitalOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT01685814 | Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance | unknown | Phase 3 | 406 | Wuerzburg University HospitalOTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT03523468 | Curative Effect and Quality of Life Between Uniportal and Open Sleeve Lobectomy for Central Type Lung Cancer | unknown | Phase 3 | 200 | Lei JiangOTHER | 1 | Apr 25, 2023 | clinicaltrials |
| NCT03958890 | A Clinical Trial Comparing HLX10 With Placebo Combined With Chemotherapy (Cisplatin + 5-fu) in the First-line Treatment of Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ESCC) | unknown | Phase 3 | 489 | Shanghai Henlius BiotechINDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05816668 | Tranexamic Acid's Effects in Patients Undergoing Laparoscopic Radical Prostatectomy(Transamin) | unknown | Phase 3 | 122 | Instituto do Cancer do Estado de São PauloOTHER | 0 | Apr 18, 2023 | clinicaltrials |
| NCT05817201 | Toripalimab Plus Radiotherapy for Elderly Esophageal Cancer Patients Treated With Non-chemotherapy Strategy | unknown | Phase 2 / Phase 3 | 60 | Taizhou HospitalOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT01675219 | Fluorescence Cystoscopy and Optimized MMC in Recurrent Bladder Cancer (FinnBladder 9) | unknown | Phase 3 | 400 | Turku University HospitalOTHER_GOV | 1 | Apr 13, 2023 | clinicaltrials |
| NCT04792749 | Clinical Effects of Metformin on Fertility-sparing Treatment for Early Endometrial Cancer | unknown | Phase 3 | 77 | Samsung Medical CenterOTHER | 1 | Apr 13, 2023 | clinicaltrials |
| NCT05802992 | The Efficacy and Safety of Colchicine Combined With Conventional Therapy in Multiple Myeloma Patients | unknown | Phase 3 | 30 | Affiliated Hospital of Nantong UniversityOTHER | 1 | Apr 7, 2023 | clinicaltrials |
| NCT03391934 | Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux® (Merck) in Metastatic Colorectal Cancer | unknown | Phase 3 | 234 | CinnagenINDUSTRY | 1 | Apr 5, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Sep 29, 2023source: clinicaltrials